MENU
CYCN
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Cyclerion Therapeutics (CYCN) Ownership - Who owns Cyclerion Therapeutics?
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases... Show more
Profile
Industry
N/A
Address
245 First Street
Phone
+1 857 327-8778
Employees
1
Web
https://www.cyclerion.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
7M
P/E Ratio
N/A
Total Cash
3.23M
Projected Growth
N/A
Total Debt
N/A
Revenue
2M
Risk (Beta)
1.36
Dividend Yield
N/A
Total Cash/Share
1.27
Total Debt/Equity
N/A
Revenue/Share
0.79 USD as % of share price
Fundamentals
CYCN
Capitalization
7M
P/E Ratio
N/A
Risk (Beta)
1.36
Dividend Yield
N/A
Total Cash
3.23M
Total Cash/Share
1.27
Total Debt
0
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.79%
Revenue
2M
ROE
N/A
Book Value
8.85M
P/B Ratio
0.79
Cash Flow
N/A
Earnings
-1.21
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
0
Current Ratio
5.83
Current Revenue Per Employee
1806000.00
Dividends Per Share - Security
N/A
EBITDA
-3.63M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-26.64
Shares Held By Institutions
1.89M
Shares Outstanding - Current
2.55M
Total Liabilities
725K
Total Volume MTD
N/A
Value
1
Gain YTD
-14.596
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a developer of pharmaceutical products for serious and orphan diseases
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
245 First Street
Phone
+1 857 327-8778
Employees
1
Web
https://www.cyclerion.com